Type 2 diabetes has an increasing prevalence. Life expectancy is dominated by cardiovascular risk, which is the leading cause of death in these patients. Up to one third of diabetic patients will develop diabetic nephropathy related to micro-angiopathy. Renal impairment further increases cardiovascular risk. Reducing cardiovascular morbidity and mortality is a major public health issue, as well as early preventing and managing chronic kidney disease (CKD). Good glycemic control prevents the micro-vascular complications of the disease (retinopathy, nephropathy, etc.) and, more recently recognized through prolonged monitoring of the VADT cohort, prevents cardiovascular complications. Control of blood pressure and dyslipidemia are essential in primary or secondary cardiovascular prevention. In addition, the blockers of the renin-angiotensin system slow down the progression of the MRC. Elderly patients with chronic kidney disease (CKD) form another growing group of the nephrologist daily patient pool. Especially for very elderly patients with comorbidities, the question of favoring conservative treatment rather than starting or pursuing dialysis may arise. Survival and quality of life are indeed not necessarily better in elderly patients undergoing dialysis, complications can occur eventually leading to discontinuation, and are occasionally associated with a feeling of stubbornness. Creation of prognostic score is a useful tool to help the decision-making process. However, dialogue with the patient and his/her family, as well as multidisciplinary collaboration remain fundamentals to determine the most suitable care.
Keywords: Antiagrégant plaquettaire; Antiplatelet agent; BSRA; Blood glucose; Blood pressure; Chronic kidney disease; Concertation; Conservative treatment; Diabetes; Diabète; Dialogue; Dialyse; Dialysis; Dyslipidaemia; Dyslipidémie; Glycémie; Maladie rénale chronique; Morbi-mortalité; Mortality and cardiovascular; Pression artérielle; Prognostic score; RAAS blockade; Score pronostique; Traitement conservateur; cardiovasculaire; events.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.